- Home
- RVPH vs GNLX Comparison
RVPH vs GNLX Comparison
Compare RVPH & GNLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVPH
- GNLX
- Stock Information
- Founded
- RVPH 2006
- GNLX 2001
- Country
- RVPH United States
- GNLX United States
- Employees
- RVPH N/A
- GNLX N/A
- Industry
- RVPH Biotechnology: Pharmaceutical Preparations
- GNLX Biotechnology: Pharmaceutical Preparations
- Sector
- RVPH Health Care
- GNLX Health Care
- Exchange
- RVPH Nasdaq
- GNLX Nasdaq
- Market Cap
- RVPH 88.0M
- GNLX 85.0M
- IPO Year
- RVPH N/A
- GNLX 2023
- Fundamental
- Price
- RVPH $2.06
- GNLX $4.46
- Analyst Decision
- RVPH Strong Buy
- GNLX Strong Buy
- Analyst Count
- RVPH 5
- GNLX 4
- Target Price
- RVPH $11.40
- GNLX $18.25
- AVG Volume (30 Days)
- RVPH 2.2M
- GNLX 293.9K
- Earning Date
- RVPH 11-14-2024
- GNLX 03-31-2025
- Dividend Yield
- RVPH N/A
- GNLX N/A
- EPS Growth
- RVPH N/A
- GNLX N/A
- EPS
- RVPH N/A
- GNLX N/A
- Revenue
- RVPH N/A
- GNLX $8,000.00
- Revenue This Year
- RVPH N/A
- GNLX N/A
- Revenue Next Year
- RVPH N/A
- GNLX N/A
- P/E Ratio
- RVPH N/A
- GNLX N/A
- Revenue Growth
- RVPH N/A
- GNLX N/A
- 52 Week Low
- RVPH $0.60
- GNLX $1.60
- 52 Week High
- RVPH $4.83
- GNLX $9.82
- Technical
- Relative Strength Index (RSI)
- RVPH 56.56
- GNLX 73.13
- Support Level
- RVPH $1.78
- GNLX $3.20
- Resistance Level
- RVPH $1.91
- GNLX $4.23
- Average True Range (ATR)
- RVPH 0.18
- GNLX 0.53
- MACD
- RVPH -0.00
- GNLX 0.09
- Stochastic Oscillator
- RVPH 86.00
- GNLX 88.15
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.
About GNLX Genelux Corporation
Genelux Corp is a clinical-stage biopharmaceutical company. The company focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive or difficult-to-treat solid tumor types. Its pipeline products include Olvi-Vec (olvimulogene nanivacirepvec) and others.